Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate, which is scheduled to be evaluated 6 months from the completion of enrollment.  This global study, conducted by Janssen has completed enrollment of the planned 110 patients in April of 2013.
  • Phase Ib dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin Lymphoma (DLBCL, MCL, FL). The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP. With a recommended Phase II dose established, the study is currently in the expansion phase in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, has been fully accrued. An update on the dose escalating phase of this study will be provided at ASCO, 2013.
  • Phase II study of ibrutinib in patients with R/R MM. This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in patients with R/R MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. Pharmacyclics anticipates an update on this program will be provided by year end 2013.
  • Phase II study of ibrutinib in patients with R/R follicular lymphoma (FL). This is a multi-center, global study of ibrutinib in patients with chemoimmunotherapy-resistant FL, whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. The primary endpoint of this study is ob
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... 2, 2014 According to ... Research "Latin America Home Healthcare Market (By Device ... Devices, Mobility Assist Devices and Medical Supplies; By ... Therapy and Unskilled Home Healthcare Services) - Industry ... - 2020" the Latin American Home Healthcare market ...
    (Date:9/2/2014)... , Sept. 2, 2014   Santa Clara dentist ... a special promotion for Invisalign. Invisalign is an orthodontic ... wires. It is often the orthodontic treatment of choice ... and aesthetics of it. For a limited time, patients ... significant savings from the usual cost. This offer cannot ...
    (Date:9/2/2014)...    - Los datos ... antitrombóticos no utilizados óptimamente para prevenir la apoplejía ... de GARFIELD-AF en el ESC CONGRESS 2014 ofrecen ... de pacientes en riesgo de sufrir apoplejía en ... Los datos de casi 12.500 pacientes reclutados en ...
    Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
    ... Oct. 6 According to Millennium Research Group ... intelligence, growth in the $2 billion US cardiac ... the expanded approval of Boston Scientific,s chronic resynchronization ... I and II patients. The New ...
    ... Oct. 6 e-MDs, an industry leader in ... (EHRs) and practice management (PM) solutions,  congratulates  the ... Family Medicine of Fort Collins, CO, for their ... of Excellence recipients.  The Healthcare Information and Management ...
    Cached Medicine Technology:Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
    (Date:9/2/2014)... (HealthDay News) -- Many people believe that marijuana is ... "As more people are able to obtain and ... recreational use, people are less likely to perceive it ... psychiatrist at Massachusetts General Hospital,s Center for Addiction Medicine, ... shows that cannabis use can have significant consequences, and ...
    (Date:9/2/2014)... Mass. (PRWEB) September 02, 2014 Healthcare ... latest and most complete oncology guidelines available at the ... Health and the National Comprehensive Cancer Network® ... with other evidence and guidelines in the content available ... , NCCN, a not-for-profit alliance of 25 of ...
    (Date:9/2/2014)... involving mice suggests that the key to more youthful ... In a report published in the Journal ... from the lungs of old mice had different responses ... mice, but these changes were reversed by ibuprofen. , ... immune function," said Joanne Turner, Ph.D., a researcher involved ...
    (Date:9/2/2014)... Nanomedicine is essentially based on ... and/or prevention of diseases and infections. Nanotechnology-based drugs ... and oncology diseases. , Nanomedicine is based ... nanoparticles, their medical usages, and their actions within ... for research in this domain, and scientists are ...
    (Date:9/2/2014)... Durable Medical Goods manufacture ThermoTek , announced today ... LeaseQ, Inc. to help customers acquire capital goods faster ... breakthrough finance shopping platform has enabled businesses to quickly ... their business. , Said LeaseQ Vice President Cory ... team to provide customers faster access to capital and ...
    Breaking Medicine News(10 mins):Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2
    ... ,better for you, options; portion-controlled treats remain popular this ... ... Oct. 1 For the 93 percent of kids who will,trick-or-treat ... ever before, including more health-minded product options,available alongside the classic treats, ...
    ... ZURICH, Switzerland, October 1 , - Share Exchange Offer to ... & Johnson - ISIN: US4781601046 - Symbol: JNJ, The K&N ... every 1 Johnson & Johnson share a change into 1 share ... The offer period starts on 13th October 2008 and ends ...
    ... of almost 1,500 kidney cancer patients treated at Memorial ... as much kidney tissue as possible may improve overall ... at the time their cancer is diagnosed. The finding ... function appear to be increasing. , "In patients who ...
    ... is a fact that,Multi-Drug Resistant organisms are on ... medicines. According to the World Health Organization,(WHO) these ... and mortality rates, which has led to a ... safe, natural and,complementary solutions to this growing problem., ...
    ... says physicians have unique opportunity to help parents and ... ... Washington, DC (Vocus) October 1, 2008 ... their families understand the http://www.childrensnational.org/?utm_source=pressrelease&utm_medium=9_30&utm_campaign=driving_safety [importance of responsible driving], ...
    ... on the horizon, dentists, ,as well as all other medical practitioners, ... Flasch, of Flasch Business Expansion. An award winning consultant with over ... expand their practices using precise business strategies. , ... ...
    Cached Medicine News:Health News:Latest Trick-or-Treats Give You Something Good to Eat 2Health News:Latest Trick-or-Treats Give You Something Good to Eat 3Health News:Latest Trick-or-Treats Give You Something Good to Eat 4Health News:Research suggests doctors should consider kidney-sparing surgery 2Health News:Research suggests doctors should consider kidney-sparing surgery 3Health News:Argentyn 23(R) Homeopathic First Aid Gel - Another World's First by Natural-Immunogenics Corp. for Healthcare Professionals 2Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 2Health News:Healthcare Providers Can Help Reduce Teen Driving Deaths 3Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 2Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 3
    ... Insertion Through A 1.0mm Incision., ,Special Direct ... ... Comfortable Approach., ,Recessed Jaws For Improved Sub-Incisional ... Of Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed ...
    The New Easy-To-Use Disposable Diamond Knife Cleaning System Can Remove Even Baked-On Debris In Seconds. It Is Much More Effective Than Steam Or Blocks Of Styrofoam, Much Safer For Employees As Wel...
    ... Corneal Gauges Allowing The Exact,Outer Diameter Measurement ... With 0.25mm ,Increments.,Easy And Quick To Use, ... And Place Over A Cornea For Confirmation ... The USA, ...
    ... Gauge Measures 360 Degrees & Can Be Set ... Cornea. 7mm Inner Diameter & 14mm Outer Diameter ... Astigmatism Gauge That Can Be Set For AKs, ... Around The Globe., ,Marks Single Or Paired AKs, ...
    Medicine Products: